BioCryst Pharmaceuticals, Inc. (BMV:BCRX)
Mexico · Delayed Price · Currency is MXN 159.50
-38.00 (-19.24%)
At close: Aug 18, 2025
BioCryst Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2005 - 2019 |
Net Income | -35.71 | -88.88 | -226.54 | -247.12 | -184.06 | -182.81 | Upgrade |
Depreciation & Amortization | 1.28 | 1.25 | 1.66 | 1.44 | 0.78 | 0.75 | Upgrade |
Stock-Based Compensation | 81.26 | 65.41 | 55.62 | 44.7 | 34.64 | 14.79 | Upgrade |
Other Adjustments | 62.65 | 57.48 | 106.53 | 98.07 | -1.64 | 5.29 | Upgrade |
Change in Receivables | -31.91 | -22.7 | -6.1 | -21.47 | -20.82 | 13.9 | Upgrade |
Changes in Inventories | -3.12 | -4.16 | -1.45 | -12.42 | -8.77 | -7.04 | Upgrade |
Changes in Accounts Payable | -62.38 | -62.38 | -16.9 | -22.36 | 39.41 | 17.36 | Upgrade |
Changes in Accrued Expenses | - | - | - | - | 4.17 | 6.77 | Upgrade |
Changes in Unearned Revenue | - | - | -1.23 | -0.11 | 1.28 | -1.97 | Upgrade |
Changes in Other Operating Activities | -0.86 | 1.96 | -6.82 | -2.58 | -7.16 | -2.14 | Upgrade |
Operating Cash Flow | 16.82 | -52.02 | -95.14 | -161.85 | -142.16 | -135.11 | Upgrade |
Capital Expenditures | -1.06 | -1.12 | -2.17 | -1.25 | -2.39 | -0.51 | Upgrade |
Purchases of Investments | -164.56 | -286.76 | -514.41 | -244.28 | -10.01 | -49.82 | Upgrade |
Proceeds from Sale of Investments | 228.13 | 320.48 | 385.08 | 117.4 | 28.2 | 43.48 | Upgrade |
Investing Cash Flow | 62.51 | 32.59 | -131.5 | -128.24 | 15.8 | -6.86 | Upgrade |
Long-Term Debt Issued | - | - | 300 | 73.07 | 293.87 | 242.47 | Upgrade |
Long-Term Debt Repaid | -1.96 | -1.7 | -241.62 | - | - | -52.42 | Upgrade |
Net Long-Term Debt Issued (Repaid) | -1.96 | -1.7 | 58.38 | 73.07 | 293.87 | 190.05 | Upgrade |
Issuance of Common Stock | 7.34 | 3.48 | 8.68 | 14.96 | 65.79 | 110.54 | Upgrade |
Repurchase of Common Stock | -5.56 | -7.54 | -2.17 | - | - | - | Upgrade |
Net Common Stock Issued (Repurchased) | 1.77 | -4.06 | 6.51 | 14.96 | 65.79 | 110.54 | Upgrade |
Other Financing Activities | - | - | -32.41 | - | - | - | Upgrade |
Financing Cash Flow | -75.9 | -5.76 | 32.49 | 88.03 | 359.67 | 300.59 | Upgrade |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | 1.36 | -0.94 | 0.36 | 0.57 | 0.07 | - | Upgrade |
Net Cash Flow | 4.78 | -26.12 | -193.79 | -201.5 | 233.39 | 158.63 | Upgrade |
Beginning Cash & Cash Equivalents | 80.21 | 112.45 | 306.24 | 507.73 | 274.35 | 115.72 | Upgrade |
Ending Cash & Cash Equivalents | 89.93 | 86.32 | 112.45 | 306.24 | 507.73 | 274.35 | Upgrade |
Free Cash Flow | 15.76 | -53.14 | -97.31 | -163.1 | -144.54 | -135.62 | Upgrade |
FCF Margin | 2.83% | -11.79% | -29.36% | -60.22% | -91.97% | -761.41% | Upgrade |
Free Cash Flow Per Share | 0.07 | -0.26 | -0.51 | -0.88 | -0.81 | -0.81 | Upgrade |
Levered Free Cash Flow | -103.81 | -155.05 | -195.07 | -211.33 | 137.15 | 20.44 | Upgrade |
Unlevered Free Cash Flow | -5.96 | -67.06 | -130.76 | -187.38 | -152.59 | -161.55 | Upgrade |
Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.